An Energy Metabolism Nanoblocker for Cutting Tumor Cell Respiration and Inhibiting Mitochondrial Hijacking from...

Area of Science:

• Oncology
• Nanomedicine
• Immunology

Background:

• Tumor therapy faces challenges due to cancer cells' adaptable energy metabolism, switching between mitochondrial respiration and glycolysis.
• Tumor cells can exploit mitochondria from immune cells, creating an additional energy pathway.
• Current strategies targeting tumor energy metabolism show limited efficacy.

Purpose of the Study:

• To develop a CD44 receptor-targeted nanoblocker for bidirectional blockade of tumor cell energy metabolism.
• To inhibit both basal respiration (oxidative phosphorylation/glycolysis) and extra respiration pathways in tumor cells.
• To enhance anti-tumor immunity by preventing mitochondrial transfer and preserving cytotoxic T lymphocytes.

Main Methods:

• Developed a hyaluronic acid nanoblocker targeting CD44 receptors.
• Loaded the nanoblocker with an oxidative phosphorylation (OXPHOS) inhibitor (nebivolol hydrochloride) and a glycolysis inhibitor (3-bromopyruvate).
• Administered L-778123 hydrochloride intraperitoneally to inhibit mitochondrial transfer.

Main Results:

• The nanoblocker effectively inhibited basal respiration (OXPHOS and glycolysis) in tumor cells.
• Inhibition of mitochondrial transfer blocked the extra respiratory pathway and prevented cytotoxic T lymphocyte depletion.
• Demonstrated high efficacy and safety in both in vitro and in vivo experiments.

Conclusions:

• The developed nanoblocker strategy offers a novel approach to deplete tumor cell energy.
• This method synergistically enhances effector immune cells, promoting systemic anti-tumor immune effects.
• Represents a paradigm shift in nanomedicine for energy metabolism-based tumor therapy.